Biography:

I have completed my MD at the age of  36  years from Minia University and postdoctoral studies from Minia University also. I am now a professor and chairman of the department of dermatology, andrology, and STDs in Minia University Hospital. I have published more than 10 papers in international journals.

Abstract:

Background: Melasma is an acquired disorder of symmetrical hyperpigmentation. Several treatment methods are available for patients with melasma, including topical compounds, broad‐spectrum photoprotection, camouflage, chemical peels, and laser and light therapies which represent potentially promising options for patients who are refractory to other modalities.

Objective: To evaluate and compare the clinical, histopathological, and immunohistochemical changes in melasma after fractional Er:YAG laser versus fractional Er:YAG laser and topical steroids.

Methods: Twenty‐two patients were treated with fractional Er:YAG laser on both sides of the face with the use of topical steroid only on the left side to make left to right side comparison. Clinical evaluation, histopathological, and immunohistochemical assessment for skin specimens were performed before treatment and 3 months after the end of sessions.

Results: Treatment by fractional Er:YAG laser on the right side showed significant decrease in MASI score with clinical outcome which considered as excellent in three patients (13.6%), very good in six (27.2%), good in eight (36.3%), and fair in five (22.7%) with significant decrease in basal pigmentation and reorganization of dermal

collagen and decreased number of MART1‐positive cells. After combined therapy, the decrease in MASI score was highly significant with the clinical outcome which considered as excellent in six patients (27.2%), very good in 10 (45.4%), good in three (13.6%), and fair in three (13.6%). The histological changes were highly evident and more significant.

Conclusion: Clinical, histopathological, and immunohistochemical improvement was evident on both sides, with the more significant better outcome with the use of combined therapy on the left side. However, combined therapy was more beneficial for Fitzpatrick skin type III rather than type IV.

KEYWORDS

fractional erbium YAG laser, melasma, topical steroids

Biography:

Danilo De Gregorio is a plastic surgeon with 18 years extensive experience and expertise in aesthetic medicine and all procedure of cosmetic surgery. He has established several renowned aesthetic medical centers across Italy.

Dr. De Gregorio graduated at Perugia University, pursued a Postgraduate University Masters in Aesthetic Medicine and Surgery at the University of San Marino and "La Sapienza" of Roma, and obtained a position as Associate Professor of Aesthetic Medicine and Surgery from 2009 to 2011 at the same University. He is an active faculty member of the International Society of Surgical Anatomy (SIACH) where he teaches clinically oriented anatomy through detailed cadaver dissections, and he is Senior Faculty at ECAMS where he teaches in anatomy courses on Facelifting, Blepharoplasty, and Non-Surgical Facia Transformation.

He divides his time between his teaching commitments in Nice ( France), his busy aesthetic medicine and surgery practices in Perugia, Roma, Firenze, Bologna, Mantova,  Verona, and Bolzano (Italy), and collaboration as Visiting Professor in manifold private Clinic worldwide (Sweden, Croatia, Uk)

Abstract:

Introduction: Calcium hydroxylapatite is one of the most studied materials in the world for its use in various surgical branches and a dermal filler (FDA approved) widely used both for the correction of wrinkles, and moderate or severe facial folds, and to reconstitute lost facial volumes. The abstract exposes our personal experience in the off-label use of calcium hydroxylapatite in the global rejuvenation of the face due to the volumetric increase of the chin, and of the labial-mental groove, correction of the marionette lines, of the pre-jowl furrow , of the zygomatic-malar area, of the peri and supra-orbital and temporal area through a few key access points.

Aims: The objective of this work will consider the evolution in a short period in the use of calcium hydroxylapatite [Radiesse (®)] in aesthetic medicine, providing a new methodology of approach to facial rejuvenation in its three-dimensionality with a protocol of detailed injection with a few key access points for a global approach to facial aging.

Materials and methods: The technique that uses a few key points of access through the cannula limits the formation of hematomas of the face due to its minimum traumatic, allowing the product to be distributed to the deep and superficial anatomical layers. The calcium drossiapatite vials are used in pure or diluted form (off-label procedure) with 1% physiological saline/lidocaine hydrochloride solution in 1: 1 or 1: 0.7 ratio using Luer-lock connectors and syringes from 5 ml.

Results : This article is our personal up-to-date review of the injective procedure of calcium hydroxylapatite [Radiesse (®)] in aesthetic medicine through its use in pure or diluted form (off-label), including a detailed injection protocol using a few key- point for a full face liquid lifting Thanks to the unique properties of calcium hydroxylapatite and its stimulating and restructuring action, it is possible to provide a stimulus to the production of linking and elastic, and to the increase of the dermal matrix, with a relaxing effect, toning and firming of the face.

Conclusions: Calcium hydroxylapatite [Radiesse (®)] is a very effective filler for the restoration of the volumes of many areas of the face and its use is associated with a good standard of safety established over the years: its use with an off-site method thanks to its characteristics of high elasticity and viscosity, the label exploits its ability to induce the long-term formation of the dermal matrix rich in collagen and elastin, making it an ideal agent for an approach to the restoration of facial volumes in a global manner.

Biography:

Dr.Niraja Nelogi has completed MBBS from Rajiv Gandhi University of health science and Diploma in Dermatology and Venereology from Maharashtra medical council in INDIA. She has a practice of 8 years in dermatology and cosmetology in Mumbai. She has done more than 2500 PRP with good results.

Abstract:

Androgenetic alopecia is a genetic disorder, androgen-dependent progressive thinning of the scalp hair in men, also seen in women. It begins by 20 years of age and affects nearly 50% of men by the age of 50 years. PRP is one of the treatments for AGA which has shown significant improvement in the hair density.

PRP represents an autologous concentration of human platelets in a small volume of plasma having 4-7 times the platelet concentration above the normal blood. It is injected subcutaneously into the area of alopecia. PRP induce the proliferation of dermal papillae cells of the scalp and thereby increase the volume of the hair. PRP can be given to males and females of an age group of 18-70yrs having mild to moderate AGA. Therapy can be given at an interval of  4 weeks over a period of 3 months and the results are assessed, there is a significant clinical improvement of hair count, hair thickness, hair root strength, and alopecia patch. To conclude PRP is a simple, safe, non-allergic, cost-effective and feasible treatment for hair loss and adjuvant therapy in the management of AGA.